Lucira's molecular test provides PCR-quality results in 30
minutes in a simple single-use test
Lucira was the first at-home COVID-19 test authorized in
Canada and has been used in public
health programs and for safe travel
EMERYVILLE, Calif., March 24,
2022 /CNW/ -- Lucira Health, Inc. ("Lucira Health" or
"Lucira") (Nasdaq: LHDX), a medical technology company focused on
the development and commercialization of transformative and
innovative infectious disease tests, announced that its Lucira™
Check-It COVID-19 test can now be purchased directly by Canadian
consumers, businesses, and healthcare providers, available at
www.checkit.lucirahealth.ca.
Lucira™ Check-It COVID-19 test now
available to Canadian consumers at
www.checkit.lucirahealth.ca
Lucira was the first COVID-19 at-home test to receive
Interim Order Authorization from Health Canada when authorized in
April 2021 and has distributed nearly
1 million tests throughout Canada.
Lucira tests have been offered through Health Canada as part of its
innovative programs to protect the public and through partners Air
Canada and Switch Health allowing international travel in and out
of Canada in compliance with entry
requirements around the world.
"Lucira tests have been among the most trusted testing options
in Canada for nearly a year
because of the unique combination of PCR-quality accuracy and the
ability to test anytime, anywhere with on-the-spot results," said
Erik Engelson, Lucira Health's
President and Chief Executive Officer. "While many consumers in
Canada have been introduced to
Lucira as a key tool for safe travel, we're delighted to now offer
similar peace of mind when gathering with friends and family and
returning to the office and other in-person events."
The Lucira Check-It COVID-19 test is available now at
www.checkit.lucirahealth.ca for delivery across Canada. It's listed at $75USD, but available for a limited time for
$60USD with code LAUNCHCA at
check-out.
About Lucira Health
Lucira is a medical technology company focused on the
development and commercialization of transformative and innovative
infectious disease tests. Lucira's testing platform produces lab
quality molecular testing in a single-use, consumer-friendly,
palm-size test kit powered by two AA batteries. Lucira designed its
test kits to provide accurate, reliable, and on-the-spot molecular
test results anywhere and at any time.
Lucira tests are used by leading businesses and healthcare
organizations like Salesforce, Amazon, Air Canada, Cleveland
Clinic, Sutter Health and many more. Beyond its COVID-19 tests,
Lucira is working on new diagnostic tests including a single test
for COVID-19 & Flu as well as other infectious diseases. For
more information, visit www.lucirahealth.com.
About Lucira Check-It
Test
The Lucira™ Check-It is a Nucleic-Acid Amplification Tests
(referred to as NAAT). The test fits in the palm of your hand,
extracts genetic material from the virus and amplifies it, similar
to PCR lab tests, to detect the presence of virus earlier and more
accurately than antigen tests. The test uses an approach called
reverse transcriptase loop-mediated isothermal amplification
(RT-LAMP). It was designed and tested extensively for individuals
to use independently and does not require a physician's
prescription or supervised assistance.
There is no additional equipment to purchase, such as a reader
or instrument. Each Lucira test contains everything needed to run a
single COVID-19 test. Users get the test device, two AA batteries,
sample vial, swab, and simple instructions.
Forward Looking
Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Words such
as "can," "plans," "will," "may," "anticipates," "expects,"
"potential," and similar expressions are intended to identify
forward-looking statements. These forward-looking statements are
based upon Lucira's current expectations and involve assumptions
that may never materialize or may prove to be incorrect. Actual
results could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, including Lucira's ability to increase production,
streamline operations and increase product availability; the
success of Lucira's test platform with COVID-19 including its
variants; the extent and duration of the COVID-19 pandemic and
Lucira's expectations regarding customer and user demand for its
COVID-19 test kit; Lucira's ability to obtain and maintain
regulatory approval for its test kits, including Lucira's existing
Emergency Use Authorization for its COVID-19 test kits and LUCI
Pass; the performance of, and Lucira's reliance on, third parties
in connection with the commercialization of its test kits,
including Jabil Inc., Switch Health and Lucira's single-source
suppliers; Lucira's ability to successfully continue to expand
internationally; any impact on Lucira's ability to market its
products; demand for Lucira's products due to deferral of
procedures using its products or disruption in its supply chain;
Lucira's ability to achieve or sustain profitability; Lucira's
ability to gain market acceptance for its products and to
accurately forecast and meet customer demand; Lucira's ability to
compete successfully; Lucira's ability to enhance and expand its
product offerings; Lucira's ability to accurately predict continued
expansion; Lucira's ability to accurately forecast revenue;
development and manufacturing problems; capacity constraints or
delays in production of Lucira's products; maintenance of coverage
and adequate reimbursement for procedures using Lucira's products;
and product defects or failures. These and other risks and
uncertainties are described more fully in the "Risk Factors"
section and elsewhere in Lucira's filings with the Securities and
Exchange Commission and available at www.sec.gov, including in its
most recent Annual Report on Form 10-K and Quarterly Report on Form
10-Q. Any forward-looking statements that we make in this
announcement speak only as of the date of this press release, and
Lucira assumes no obligation to update forward-looking statements
whether as a result of new information, future events or otherwise
after the date of this press release, except as required under
applicable law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lucira-healths-pcr-quality-at-home-covid-19-test-now-available-direct-to-consumers-in-canada-301509710.html
SOURCE Lucira Health